We claim:

1. A method of extending the duration of the therapeutic effect of botulinum toxin in an animal comprising the steps of administering a botulinum toxin to treat a condition or disorder and administering an inhibitor of the protein tyrosine kinase pathway in an amount sufficient to extend the duration of the effect of botulinum toxin therapy.

2. The method of claim 1, wherein said inhibitor of the protein tyrosine kinase pathway is a compound of formula:



wherein V, W and X are selected from the group consisting of hydro, hydroxyl, alkoxy, halo, an ester, an ether, a carboxylic acid group, a pharmaceutically acceptable salt of a carboxylic acid group, and -SR, in which R is hydrogen or an alkyl group, and Y is selected from the group consisting of oxygen, sulfur, C(OH), and C=O, and Z is selected from the group consisting of hydro and $C(O)OR_1$, wherein R_1 is an alkyl, or a protein tyrosine kinase-inhibiting prodrug or pharmaceutically acceptable salt thereof.

3. The method of claim 2, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.

4. The method of claim 2, wherein said condition or disorder is a condition or disorder involving the autonomic nervous system.

5. The method of claim 2, wherein said inhibitor of the protein tyrosine kinase pathway is genistein.

6. The method of claim 5, wherein the dose of genistein administered is from 1 mg/kg/day to about 100 mg/kg/day.

7. The method of claim 5, wherein the dose of genistein administered is from 15 mg/kg/day to about 50 mg/kg/day.

8. The method of claim 5, wherein said botulinum toxin is botulinum toxin type A.

9. The method of claim 5, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G or a combination thereof.

10. The method of claim 8, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.

11. The method of claim 8, wherein said condition or disorder is a condition or disorder involving the autonomic nervous system.

12. The method of claim 9, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.

13. The method of claim 9, wherein said condition or disorder is a condition or disorder involving the autonomic nervous system.

14. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G or a combination thereof.

15. The method of claim 1, wherein the botulinum toxin is botulinum toxin type A.

16. The method of claim 1, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.

17. The method of claim 1, wherein said condition or disorder is a condition or disorder involving the autonomic nervous system.

18. The method of claim 15, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.

19. The method of claim 15, wherein said condition or disorder is a condition or disorder involving the autonomic nervous system.

20. The method of claim 14, wherein said condition or disorder is a condition or disorder involving the skeletal neuromuscular system.